Scotts Miracle-Gro/$SMG
1D1W1MYTD1Y5YMAX
Capital at risk
About Scotts Miracle-Gro
Scotts Miracle-Gro is the largest purveyor of home lawn and gardening products in the US. The company sells a broad range of lawncare products, including grass seed, fertilizer, and lawn-related weed, animal, and disease control. US consumer typically generates the vast majority of companywide revenue and profits. Its lawncare and gardening products are well-recognized brands in the US, including Scotts, Miracle-Gro, Roundup, Ortho, and Tomcat. Over half of revenue typically comes from Home Depot and Lowe's, as Scotts' products are featured at both home improvement retailers.
- Ticker
- $SMG
- Sector
- Materials
- Primary listing
- NYSE
- Employees
- 5,200
- Headquarters
- Marysville, United States
- Website
- scottsmiraclegro.com
SMG Metrics
BasicAdvanced
$3B
41.96
$1.25
1.83
$2.64
5.04%
Price and volume
Market cap
$3B
Beta
1.83
52-week high
$75.34
52-week low
$52.00
Average daily volume
864K
Dividend rate
$2.64
Financial strength
Current ratio
1.215
Quick ratio
0.667
Long term debt to equity
-8.799
Total debt to equity
-10.126
Dividend payout ratio (TTM)
208.93%
Interest coverage (TTM)
4.29%
Profitability
EBITDA (TTM)
552.5
Gross margin (TTM)
32.16%
Net profit margin (TTM)
2.12%
Operating margin (TTM)
13.94%
Effective tax rate (TTM)
37.92%
Revenue per employee (TTM)
$670,000
Management effectiveness
Return on assets (TTM)
9.70%
Return on equity (TTM)
-81.61%
Valuation
Price to earnings (TTM)
41.958
Price to revenue (TTM)
0.873
Price to book
-14.6
Price to tangible book (TTM)
-3.8
Price to free cash flow (TTM)
11.544
Free cash flow yield (TTM)
8.66%
Free cash flow per share (TTM)
4.536
Dividend yield (TTM)
5.04%
Forward dividend yield
5.04%
Growth
Revenue change (TTM)
3.71%
Earnings per share change (TTM)
35.27%
3-year revenue growth (CAGR)
-1.73%
10-year revenue growth (CAGR)
2.17%
3-year earnings per share growth (CAGR)
-19.17%
10-year earnings per share growth (CAGR)
-13.15%
10-year dividend per share growth (CAGR)
3.45%
What the Analysts think about SMG
Analyst ratings (Buy, Hold, Sell) for Scotts Miracle-Gro stock.
Analyst projections of the future price of Scotts Miracle-Gro stock.
Bulls say / Bears say
Scotts Miracle-Gro’s fiscal Q2 net sales rose 5% to $1.46 billion, beating analyst estimates and underscoring resilient consumer demand during the peak spring season (Reuters)
Adjusted EBITDA increased by 9% year-over-year in Q2, driven by over 200 basis points of gross margin expansion, reflecting effective pricing and cost management (Reuters)
Net leverage improved to 3.71× from 4.41× year-over-year, enhancing the company’s balance sheet flexibility and supporting potential shareholder returns (Reuters)
J.P. Morgan downgraded SMG to Neutral from Overweight, warning that raw material costs could rise by $45–50 million in fiscal 2027, creating uncertainty around earnings growth (Reuters)
Bayer’s removal of glyphosate from its consumer Roundup formulations to mitigate litigation risk may undercut SMG’s licensed Roundup revenue stream and necessitate product reformulation (Reuters)
Scotts’ Q3 fiscal 2026 U.S. Consumer segment net sales growth decelerated to just 0.3% year-over-year, indicating demand plateauing post-peak season (SEC)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
SMG Financial Performance
Revenues and expenses
SMG Earnings Performance
Company profitability
Upcoming events
No upcoming events
SMG News
AllArticlesVideos
Scotts Miracle-Gro Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of The Scotts Miracle-Gro Company - SMG
Business Wire2 weeks ago
Scotts Miracle-Gro Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of The Scotts Miracle-Gro Company - SMG
Business Wire1 month ago
Top 3 Ancillary Marijuana Stocks to Watch in August 2026
MarijuanaStocks2 months ago
Funds containing SMG
AllUSDGBPEUR
Fund name | Fund size | $SMG weighting |
|---|---|---|
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.07% |
SPDR S&P 400 US Mid Cap£SPX4 | £4.7B | 0.07% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.03% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.